Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Celso Arango

Showing results (71-80 of 570) with videos related to

Pageof 57
Sort By:
Schizophrenia Research|December 8, 2007
Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS studyJavier Rejas, Julio Bobes, Celso Arango, et al.
Neuroscience and Biobehavioral Reviews|December 17, 2017
A quantitative approach to neuropsychiatry: The why and the howMartien J Kas, Brenda Penninx, Bernd Sommer, et al.
Schizophrenia Bulletin|January 26, 2018
Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression AnalysisDavid Fraguas, Covadonga M Díaz-Caneja, Laura Pina-Camacho, et al.
Schizophrenia Research|July 9, 2008
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS studyCelso Arango, Julio Bobes, Pedro Aranda, et al.
Schizophrenia Research|November 25, 2006
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS StudyJulio Bobes, Celso Arango, Pedro Aranda, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 28, 2011
Placebo effect in child and adolescent psychiatric trialsMara Parellada, Carmen Moreno, Miguel Moreno, et al.
Medicina Clinica|June 28, 2007
[Adaptation and validation into Spanish of Schedule for the Deficit Syndrome]Miguel Bernardo, Emilio Fernández-Egea, Amparo Torras, et al.
Schizophrenia Bulletin|September 16, 2010
The continuum of psychotic symptoms in the general population: a cross-national studyRoberto Nuevo, Somnath Chatterji, Emese Verdes, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|February 5, 2013
A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugsJosep Darbà, Lisette Kaskens, Pedro Aranda, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|June 7, 2014
Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorderCovadonga M Díaz-Caneja, Carmen Moreno, Cloe Llorente, et al.
Pageof 57

Showing results (71-80 of 570) with videos related to

Sort By:
Pageof 57
Schizophrenia Research|December 8, 2007
Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS studyJavier Rejas, Julio Bobes, Celso Arango, et al.
Neuroscience and Biobehavioral Reviews|December 17, 2017
A quantitative approach to neuropsychiatry: The why and the howMartien J Kas, Brenda Penninx, Bernd Sommer, et al.
Schizophrenia Bulletin|January 26, 2018
Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression AnalysisDavid Fraguas, Covadonga M Díaz-Caneja, Laura Pina-Camacho, et al.
Schizophrenia Research|July 9, 2008
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS studyCelso Arango, Julio Bobes, Pedro Aranda, et al.
Schizophrenia Research|November 25, 2006
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS StudyJulio Bobes, Celso Arango, Pedro Aranda, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 28, 2011
Placebo effect in child and adolescent psychiatric trialsMara Parellada, Carmen Moreno, Miguel Moreno, et al.
Medicina Clinica|June 28, 2007
[Adaptation and validation into Spanish of Schedule for the Deficit Syndrome]Miguel Bernardo, Emilio Fernández-Egea, Amparo Torras, et al.
Schizophrenia Bulletin|September 16, 2010
The continuum of psychotic symptoms in the general population: a cross-national studyRoberto Nuevo, Somnath Chatterji, Emese Verdes, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|February 5, 2013
A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugsJosep Darbà, Lisette Kaskens, Pedro Aranda, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|June 7, 2014
Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorderCovadonga M Díaz-Caneja, Carmen Moreno, Cloe Llorente, et al.
Pageof 57